Open AccessANTINOCYCEPTIVE EFFECT OF A SYSTEMIC ADMINISTRATION OF PALMITOYLETHANOLAMIDE, STEAROYLETHANOLAMIDE AND DYNCLOFENAC IN RATS WITH EXPERIMENTAL NEUROGENIC PAIN SYNDROME
Author(s) -
А. Ю. Молчанова,
И. П. Жаворонок,
E. I. Pekhtereva,
Olga Antipova,
Т. Б. Мелик-Касумов,
T. O. Pavlyut,
A. I. Vasil’kevich,
M. A. Kisel
Publication year - 2018
Publication title -
vescì nacyânalʹnaj akadèmìì navuk belarusì. seryâ medycynskìh navuk
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.138
H-Index - 1
eISSN - 2524-2350
pISSN - 1814-6023
DOI - 10.29235/1814-6023-2018-15-3-331-
Subject(s) - palmitoylethanolamide , diclofenac sodium , hyperalgesia , diclofenac , medicine , nociception , anesthesia , pharmacology , stimulation , systemic administration , biology , receptor , in vivo , microbiology and biotechnology , cannabinoid receptor , agonist
The antinociceptive effect of palmitoylethanolamide (PEA), stearoyl- ethanolamide (SEA) and sodium diclofenac in experimental peripheral neuropathy in rats was studied. Intraperitoneal administration of PEA one hour prior to stimulation on the 7th and 14th day significantly weakened CCI-induced mechanical hyperalgesia by increasing PNR by 23.1 and 31.8 %, respectively. SEA under similar conditions increased PNR by 27.9 and 30.3 %, while diclofenac – by 29.0 and 26.2 %. New data were obtained and pointed that stearoylethanolamide effectively weakens mechanical hyperalgesia caused by neuropathy. The antinociceptive effects of these fatty acid derivatives in the modeling of neurogenic pain syndrome are comparable to those of sodium diclofenac. It seems advisable to consider PEA and SEA as a basis for drugs, whose addition to treatment regimens of neuropathic pain will increase its effectiveness.